257 related articles for article (PubMed ID: 37466731)
1. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.
Wang X; Chen F; Guo N; Gu Z; Lin H; Xiang X; Shi Y; Han B
Cancer Chemother Pharmacol; 2023 Oct; 92(4):253-270. PubMed ID: 37466731
[TBL] [Abstract][Full Text] [Related]
2. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
Saeheng T; Na-Bangchang K; Karbwang J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
[TBL] [Abstract][Full Text] [Related]
3. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
Min JS; Bae SK
Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
[TBL] [Abstract][Full Text] [Related]
4. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
5. Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction.
Prieto Garcia L; Lundahl A; Ahlström C; Vildhede A; Lennernäs H; Sjögren E
CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1194-1209. PubMed ID: 35722750
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
[TBL] [Abstract][Full Text] [Related]
7. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.
Frechen S; Solodenko J; Wendl T; Dallmann A; Ince I; Lehr T; Lippert J; Burghaus R
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):633-644. PubMed ID: 33946131
[TBL] [Abstract][Full Text] [Related]
8. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
[TBL] [Abstract][Full Text] [Related]
9. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
[TBL] [Abstract][Full Text] [Related]
10. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
11. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
[TBL] [Abstract][Full Text] [Related]
12. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
13. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
[TBL] [Abstract][Full Text] [Related]
14. Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates.
Allegaert K; Abbasi MY; Annaert P; Olafuyi O
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):301-312. PubMed ID: 35796504
[TBL] [Abstract][Full Text] [Related]
15. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
16. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
[TBL] [Abstract][Full Text] [Related]
17. Usage of In Vitro Metabolism Data for Drug-Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration.
Lee J; Yang Y; Zhang X; Fan J; Grimstein M; Zhu H; Wang Y
J Clin Pharmacol; 2021 Jun; 61(6):782-788. PubMed ID: 33460193
[TBL] [Abstract][Full Text] [Related]
18. [Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model].
Yu MM; Gao ZW; Chen XY; Zhong DF
Yao Xue Xue Bao; 2014 Dec; 49(12):1684-8. PubMed ID: 25920197
[TBL] [Abstract][Full Text] [Related]
19. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
20. Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncology.
Yoshida K; Budha N; Jin JY
Clin Pharmacol Ther; 2017 May; 101(5):597-602. PubMed ID: 28074611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
